Saibeni Simone, Meucci Gianmichele, Papi Claudio, Manes Gianpiero, Fascì-Spurio Federica
U.O. Gastroenterologia, Ospedale di Rho, Azienda Ospedaliera G. Salvini, Corso Europa 250, 20017, Rho (MI), Italy.
Expert Rev Gastroenterol Hepatol. 2014 Nov;8(8):949-62. doi: 10.1586/17474124.2014.924396. Epub 2014 May 31.
At present, therapy of inflammatory bowel disease is still far from being fully satisfactory; old drugs like steroids, for instance, still represent a cornerstone in the treatment of active disease despite their associated important side effects and incomplete clinical efficacy. In the last years, new therapeutic strategies have been suggested in order to avoid or at least limit steroids use and in this direction the so-called low bioavailability steroids appeared to be a promising therapeutic weapon; however, some grey areas about their real utility and manner of use still remain. The aim of this review is to evaluate the available evidence about the use of oral budesonide and beclomethasone dipropionate in inflammatory bowel disease, to critically assess their current position in the therapeutic algorithm of these diseases and to give simple and practical indications for their use in every-day clinical practice.
目前，炎症性肠病的治疗仍远不能令人完全满意；例如，像类固醇这样的老药，尽管有重要的副作用且临床疗效不完全，但仍是治疗活动性疾病的基石。在过去几年里，为了避免或至少限制类固醇的使用，人们提出了新的治疗策略，在这个方向上，所谓的低生物利用度类固醇似乎是一种有前景的治疗手段；然而，关于它们的实际效用和使用方式仍存在一些灰色地带。这篇综述的目的是评估关于口服布地奈德和丙酸倍氯米松在炎症性肠病中应用的现有证据，批判性地评估它们在这些疾病治疗方案中的当前地位，并为其在日常临床实践中的使用提供简单实用的指导。
